Tissue Collection Protocol for Gastroesophageal Cancers
Tissue Collection for Gastro-esophageal Cancer Primary Cell Line Establishment
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Frances Allison
- Phone Number: 416-340-5446
- Email: Frances.Allison@uhn.ca
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2C4
- Recruiting
- University Health Network: Toronto General Hospital
-
Contact:
- Frances Allison
- Phone Number: 416-340-5446
- Email: Frances.Allison@uhn.ca
-
Principal Investigator:
- Gail Darling, MD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients with esophagogastric cancer and/or GERD +/- Barrett's esophagus who will undergo surgery and/or EGD as standard of care.
Exclusion Criteria:
- Patients who are not well enough to undergo surgery or EGD as standard of care.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
TIssue Collection
Only one arm will be used to collect tissue from Esophageal Adenocarcinoma
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Effectively culture, proliferate, and store primary gastro-esophageal cell lines in order to create a bank of primary esophageal / gastric cancers for research purposes
Time Frame: Ongoing
|
The primary objective of this study is to determine an effective way to culture, proliferate, and store primary gastro-esophageal cell lines in order to create a bank of primary esophageal / gastric cancers or GERD with/without Barrett's esophagus for research purposes, in addition we will be creating organoids.
|
Ongoing
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Jonathan Yeung, University Health Network, Toronto
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 14-8514
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Esophageal Cancer
-
NCT02857218WithdrawnStage IIB Esophageal Cancer AJCC v7 | Stage III Esophageal Cancer AJCC v7 | Stage IIIA Esophageal Cancer AJCC v7 | Stage IIIB Esophageal Cancer AJCC v7 | Stage IIIC Esophageal Cancer AJCC v7
-
NCT01196390CompletedEsophageal Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma | Stage IIA Esophageal Cancer AJCC v7 | Stage IIB Esophageal Cancer AJCC v7 | Stage IIIA Esophageal Cancer AJCC v7 | Stage IIIB Esophageal Cancer AJCC v7 | Stage IB Esophageal Cancer AJCC v7
-
NCT06532799RecruitingStomach Cancer | Esophageal Cancer | Stomach Cancer, Adenocarcinoma | Stomach Cancer Recurrent | Esophageal Cancer Metastatic to Bone | Esophageal Cancer Metastatic to Lung | Esophageal Cancer Metastatic to Liver
-
NCT03416244CompletedEsophageal Cancer | Gastrooesophageal Cancer | Oesophageal Cancer | GastroEsophageal Cancer | Esophageal Cancers NOS | Oesophageal Cancer Metastatic | Esophageal Cancer Metastatic | Oesophageal Cancer Nos
-
NCT03708042Not yet recruitingStage III Esophageal Cancer | Stage II Esophageal Cancer
-
NCT02959385UnknownStage III Esophageal Cancer | Stage II Esophageal Cancer
-
NCT03490292CompletedResectable Esophageal Cancer | GastroEsophageal Cancer
-
NCT02389751CompletedGastroesophageal Junction Adenocarcinoma | Stage IIA Esophageal Cancer AJCC v7 | Stage IIB Esophageal Cancer AJCC v7 | Stage IIIA Esophageal Cancer AJCC v7 | Stage IIIB Esophageal Cancer AJCC v7 | Stage IIIC Esophageal Cancer AJCC v7 | Malignant Neoplasm of the Cervical Esophagus | Malignant Neoplasm of the Thoracic Esophagus
-
NCT01745107UnknownEsophageal Neoplasm | Esophageal Cancer TNM Staging Primary Tumor (T) T3 | Esophageal Cancer TNM Staging Primary Tumor (T) T2 | Esophageal Cancer TNM Staging Regional Lymph Nodes (N) N0 | Esophageal Cancer TNM Staging Distal Metastasis (M) M0
-
NCT03087864CompletedEsophageal Cancer, Stage II | Esophageal Cancer Stage III
Clinical Trials on Tissue Collection
-
NCT03735745Completed
-
NCT06780176RecruitingBreast Cancer | Breast Neoplasms | Breast Diseases
-
NCT07325786Active, not recruitingIdentification | Wound Infection Bacterial
-
NCT07169838CompletedRegenerative Medicine | Stem Cell Banking | Perinatal Medical Waste | Umbilical Cord Stem Cells
-
NCT04068389CompletedPollution; Exposure | Lung; Premature
-
NCT02441140TerminatedStage IV Ovarian Cancer | Stage III Ovarian Cancer